Abstract 1603: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation
Peiwen Kuo(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Murali K. Addepalli(Nektar Therapeutics (United States)), Mekhala Maiti(Nektar Therapeutics (United States)), Christie Fanton(Nektar Therapeutics (United States)), Arunasree Lanka(Nektar Therapeutics (United States)), Ping Zhang(Ningbo University), Poornachandra Mathamsetti(Nektar Therapeutics (United States)), Peter Kirk(Immunocore (United Kingdom)), Takahiro Miyazaki(Nektar Therapeutics (United States))
Cited by 6
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403